Western Blotting (WB), ELISA, Immunofluorescence (IF)
Specificity
At least three isoforms of PLA1A are known to exist, this antibody will detect all three isoforms.
Purification
PLA1A Antibody is affinity chromatography purified via peptide column.
Immunogen
PLA1A antibody was raised against a 17 amino acid synthetic peptide near the carboxy terminus of human PLA1A. The immunogen is located within amino acids 380 - 430 of PLA1A.
PLA1A antibody can be used for detection of PLA1A by Western blot at 1 - 2 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
PLA1A Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
PLA1A antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
PLA1A Antibody: PLA1A is a phospholipase that hydrolyzes fatty acids at the sn-1 position of phosphatidylserine and 1-acyl-2-lysophosphatidylserine. This secreted protein hydrolyzes phosphatidylserine (PS) in liposomes and can also hydrolyze PS in apoptotic cells and activate platelets where the resulting 2-acyl-lysophosphatidylserine acts as a lipid mediator for mast cells, T cells, and neural cells, suggesting that a major function of PLA1A may be the production of lysophospholipid mediators. PLA1A is upregulated in rat peripheral blood cells bearing long-term surviving cardiac allograft. PLA1A is also expressed in human THP-1-derived macrophages and this expression is upregulated in cells treated with lipopolysaccharide, a TLR4 ligand. This upregulation is inhibited with corticosteroids, which are often used at high dosages to suppress chronic allograft rejection.